CompletedNot Applicable

Optical Detection of Malignancy During Percutaneous Interventions

Netherlands104 participantsStarted 2012-10

Plain-language summary

Investigation of application possibilities of optical spectroscopy within the field of oncology. Optical spectroscopy enables the possibility to specifically differentiate between different (human) tissues. The hypothesis is that incorporation of this technique into existing medical devices (e.g. biopsy needle) would enlarge the accuracy and reliability of these devices. The purpose is to improve and speed up the diagnostics and therapy of the malignancies.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with a suspicious lesion in lung or liver who are scheduled for a standard core biopsy procedure * Patient planned for percutaneous RFA of colorectal liver metastasis * Written informed consent * Patients ≥ 18 years old * Breast patients with a BIRADS score 4 or 5 General Exclusion criteria: * Patients who have higher risk of bleeding * Patients with suspected sensitivity to light; e.g. patients who have had photodynamic therapy Breast Specific Exclusion criteria: * Patients who have a history of breast cancer and/or who have received prior chemotherapy, endocrine therapy, or radiation therapy * Patients who have breast implants * Patients needing a stereotactic breast biopsy (i.e. non palpable-, ultrasound opaque lesions)

What they're measuring

Differentiation between normal and malignant tissue

Timeframe: Day 0

Trial details

NCT IDNCT01730365

SponsorPhilips Healthcare

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2015-12

View on ClinicalTrials.gov More Pulmonary Coin Lesion trials